Alex Gorsky, CEO of Johnson & Johnson
Adam Jeffery | CNBC
Johnson & Johnson announced Wednesday its early-stage human trial for a potential coronavirus vaccine will begin in the second half of July, earlier than its initial forecast of September.
“Based on the strength of the preclinical data we have seen so far and interactions with the regulatory authorities, we have been able to further accelerate the clinical development of our investigational SARS-CoV-2 vaccine, Ad26.COV2-S, recombinant,” J&J’s Chief Scientific Officer Paul Stoffels said in a press release.
The company began developing a Covid-19 vaccine in January.
It is using the same technologies it used to make its experimental…